Infigratinib
Information
- Drug Name
- Infigratinib
- Description
- Entry(CIViC)
- 15
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| cholangiocarcinoma | FGFR2 FGFR2-BICC1 | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 24122810 | Detail |
| cholangiocarcinoma | FGFR2 FGFR2-AHCYL1 | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 24122810 | Detail |
| lung squamous cell carcinoma |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 27870574 | Detail |
| breast cancer |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
B |
Predictive
|
Does Not Support
|
Sensitivity/Response | 2 | 27870574 | Detail | |
| bladder carcinoma | FGFR3 MUTATION FGFR3 MUTATION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 27870574 | Detail |
| bladder carcinoma |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
C |
Predictive
|
Does Not Support
|
Sensitivity/Response |
N/A
|
2 | 27870574 | Detail |
| cholangiocarcinoma | FGFR2 MUTATION FGFR2 MUTATION | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 27870574 | Detail |
| cholangiocarcinoma | FGFR2 FUSION FGFR2 FUSION | C |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 2 | 27870574 | Detail |
| sarcoma | FGFR1 EXPRESSION FGFR1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 3 | 27535980 | Detail |
| cholangiocarcinoma | FGFR2 FUSION FGFR2 FUSION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29182496 | Detail |
| cholangiocarcinoma | FGFR2 FUSION FGFR2 FUSION | B |
Predictive
|
Supports
|
Sensitivity/Response | Somatic | 4 | 29182496 | Detail |
| transitional cell carcinoma | FGFR3 FGFR3-TACC3 | B |
Predictive
|
Supports
|
Sensitivity/Response | 3 | 29848605 | Detail | |
| head and neck squamous cell carcinoma | FGFR1 EXPRESSION FGFR1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 26015511 | Detail |
| gastric adenocarcinoma | FGFR1 EXPRESSION FGFR1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 26637881 | Detail |
| colorectal cancer | FGFR1 EXPRESSION FGFR1 EXPRESSION | D |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
2 | 24135816 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Expression of the FGFR2-BICC1 fusion kinase in NIH... | FGFR2 | FGFR2 FGFR2-BICC1 | Sensitivity | true | CIViC Evidence | detail |
| Expression of the FGFR2-AHCYL1 fusion kinase in NI... | FGFR2 | FGFR2 FGFR2-AHCYL1 | Sensitivity | true | CIViC Evidence | detail |
| Phase 1 study of FGFR-inhibitor BGJ398 in advanced... | FGFR1 |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
Sensitivity | true | CIViC Evidence | detail |
| Phase 1 study of FGFR-inhibitor BGJ398 in advanced... | FGFR1 |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
Sensitivity | false | CIViC Evidence | detail |
| Phase 1 study of FGFR-inhibitor BGJ398 in advanced... | FGFR3 | FGFR3 MUTATION FGFR3 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Phase 1 study of FGFR-inhibitor BGJ398 in advanced... | FGFR1 |
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) FGFR1 AMPLIFICATION ( ENST00000425967.8 ) |
Sensitivity | false | CIViC Evidence | detail |
| Phase 1 study of FGFR-inhibitor BGJ398 in advanced... | FGFR2 | FGFR2 MUTATION FGFR2 MUTATION | Sensitivity | true | CIViC Evidence | detail |
| Phase 1 study of FGFR-inhibitor BGJ398 in advanced... | FGFR2 | FGFR2 FUSION FGFR2 FUSION | Sensitivity | true | CIViC Evidence | detail |
| Targeting of FGFR1 by RNA interference and small-m... | FGFR1 | FGFR1 EXPRESSION FGFR1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| This Phase II trial of BGJ398 for FGFR2 aberant ch... | FGFR2 | FGFR2 FUSION FGFR2 FUSION | Sensitivity | true | CIViC Evidence | detail |
| Eight patients with cholangiocarcinoma haboring FG... | FGFR2 | FGFR2 FUSION FGFR2 FUSION | Sensitivity | true | CIViC Evidence | detail |
| In this one-arm study, 67 patients with metastasti... | FGFR3 | FGFR3 FGFR3-TACC3 | Sensitivity | true | CIViC Evidence | detail |
| FGFR1 mRNA expression, rather than copy number alt... | FGFR1 | FGFR1 EXPRESSION FGFR1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| FGFR inhibitor BGJ398 was most effective in a gast... | FGFR1 | FGFR1 EXPRESSION FGFR1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| In vitro studies showed efficacy of FGFR inhibitor... | FGFR1 | FGFR1 EXPRESSION FGFR1 EXPRESSION | Sensitivity | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04233567 | Active, not recruiting | Phase 2 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | January 16, 2020 | December 31, 2023 |
| NCT04228042 | Completed | Phase 1/Phase 2 | Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer | July 28, 2020 | April 17, 2024 |
| NCT05145010 | Enrolling by invitation | Phase 2 | Extension Study of Infigratinib in Children With Achondroplasia (ACH) | December 6, 2021 | February 1, 2032 |
| NCT06206278 | Recruiting | Phase 2 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma | October 19, 2023 | December 2025 |
| NCT04197986 | Terminated | Phase 3 | Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | March 11, 2020 | February 28, 2023 |
| NCT04424966 | Terminated | Early Phase 1 | Infigratinib in Recurrent High-Grade Glioma Patients | July 21, 2020 | April 27, 2023 |
| NCT04504331 | Terminated | Phase 1 | Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | October 13, 2020 | October 22, 2021 |
| NCT05019794 | Unknown status | Phase 2 | Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations | May 13, 2020 | December 30, 2023 |
| NCT05222165 | Withdrawn | Phase 1/Phase 2 | Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations | October 1, 2021 | December 16, 2022 |
| NCT05510427 | Withdrawn | Phase 1 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | August 7, 2023 | August 7, 2023 |
| NCT04972253 | Withdrawn | Phase 1 | Phase I BLASST-3 Trial | December 23, 2021 | December 2023 |